Effect of urogastrone in the Zollinger-Ellison syndrome.
The effects of human urogastrone (0-25 mug. per kg. per hour intravenously) in four male patients with proven Zollinger-Ellison syndrome (z.e.s.) and in four healthy control subjects have been studied. After urogastrone in z.e.s. patients gastric acid volume and concentration decreased and basal acid output was reduced by 50-82%; the concentrations of intrinsic factor and pepsin in gastric juice increased by 60-300%; and peak plasma-gastrin concentration increased by 127-164% of basal concentration. A significant negative correlation between increase in plasma-gastrin concentration and decrease in acid output was observed (r=-0-72, P less than 0-01). Ulcer pain was relieved 30-60 minutes after the beginning of urogastrone infusion. These results suggest that urogastrone can inhibit the endogenously stimulated acid hypersecretion in z.e.s.
D000328:Adult; D003864:Depression, Chemical; D004815:Epidermal Growth Factor / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005750:Gastric Juice / Q000032:analysis / Q000378:metabolism*; D005755:Gastrins / Q000097:blood; D005768:Gastrointestinal Hormones / Q000494:pharmacology*; D006801:Humans; D007263:Infusions, Parenteral; D007437:Intrinsic Factor / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010434:Pepsin A / Q000032:analysis; D015043:Zollinger-Ellison Syndrome / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*
D005755:Gastrins; D005768:Gastrointestinal Hormones; D004815:Epidermal Growth Factor; D007437:Intrinsic Factor; D010434:Pepsin A